NovoCure Announces Positive Phase 2 PANOVA-4 Pancreatic Cancer Data

NovoCure ( (NVCR) ) has provided an update.

On March 26, 2026, Novocure reported positive topline data from its Phase 2 PANOVA-4 trial evaluating Tumor Treating Fields therapy in combination with atezolizumab, gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma. The regimen achieved a disease control rate of 74.4% in 78 patients, markedly higher than the 48% reported for gemcitabine and nab-paclitaxel alone in a historical Phase 3 control cohort.

PANOVA-4 also delivered a 34.6% objective response rate and a median overall survival of 9.7 months, with TTFields therapy showing a tolerable safety profile consistent with earlier studies. The results bolster Novocure’s bid to position TTFields as a meaningful addition to standard systemic regimens in metastatic pancreatic cancer, and the company plans to present further data at an upcoming scientific meeting.

The most recent analyst rating on (NVCR) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.

Spark’s Take on NVCR Stock

According to Spark, TipRanks’ AI Analyst, NVCR is a Neutral.

The score is held back primarily by weak financial performance, driven by persistent losses and negative free cash flow. Offsetting this, the latest earnings call included constructive guidance toward adjusted EBITDA breakeven and highlighted meaningful pipeline and regulatory progress, while technical signals are moderately supportive. Valuation remains constrained by negative earnings and no dividend.

To see Spark’s full report on NVCR stock, click here.

More about NovoCure

Novocure is a global oncology company focused on extending survival in aggressive solid tumors through the development and commercialization of its Tumor Treating Fields (TTFields) therapy. Its commercialized products are approved in select markets for adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma, supported by R&D operations across Switzerland, the U.S. and Israel.

The company’s TTFields technology uses electric fields to disrupt cancer cell division while sparing most healthy tissue, and is designed to be combined with chemotherapy, radiotherapy, immune checkpoint inhibitors and targeted therapies. Novocure is advancing multiple clinical trials in glioblastoma, non-small cell lung cancer and pancreatic cancer, aiming to broaden TTFields’ role across a range of solid tumors.

Average Trading Volume: 1,913,281

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.32B

Find detailed analytics on NVCR stock on TipRanks’ Stock Analysis page.